In:
International Journal of Cancer, Wiley, Vol. 149, No. 2 ( 2021-07-15), p. 378-386
Abstract:
What's new? For many cancers, the response to immune‐checkpoint inhibition (ICI) has been disappointing. Could a modified strategy be useful? In this pilot study of patients with metastatic gastroesophageal adenocarcinoma (mGEA), the authors found that following ICI with anti‐VEGFR/paclitaxel yielded considerably better response rates, overall survival (OS), and progression‐free survival (PFS) than either modality alone. They also found alterations in the tumor microenvironment. These results support further studies on this sequential approach to therapy, and prospective clinical trials are currently underway.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink